Elite Pharmaceuticals (Elite Pharmaceuticals) Cash-to-Debt : 0.74 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Elite Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.74.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Elite Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Elite Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ELTP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28 Med: 1.6 Max: 5.26
Current: 0.74

During the past 13 years, Elite Pharmaceuticals's highest Cash to Debt Ratio was 5.26. The lowest was 0.28. And the median was 1.60.

ELTP's Cash-to-Debt is ranked worse than
55.06% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs ELTP: 0.74

Elite Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Elite Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Elite Pharmaceuticals Cash-to-Debt Chart

Elite Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.57

0.28

1.34

3.07

2.01

Elite Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1.12	2.01	1.16	1.13	0.74

Competitive Comparison of Elite Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elite Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Cash-to-Debt falls into.

Elite Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Elite Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.832	/	(0.326	+	3.562)
	=	2.01

Elite Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.816	/	(4.37	+	3.518)
	=	0.74

Elite Pharmaceuticals (OTCPK:ELTP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Elite Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals (Elite Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Executives

Mark N Pellegrino	officer: CFO, Secretary, Treasurer	165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov	officer: Chief Commercial Officer	165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J	officer: CFO, Secretary, Treasurer	165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman	officer: CFO, Secretary, Treasurer	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer	director	C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel	director	93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc	10 percent owner	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Plassche	officer: Executive VP of Operations	165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine	director, 10 percent owner	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye	director, 10 percent owner, officer: Chief Scientific Officer	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc	10 percent owner	227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc	10 percent owner	227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim	director, 10 percent owner, officer: President & CEO	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647